azelaprag tirzepatide azelaprag - Azelapragoral BGE-105 (azelaprag) co-administered with tirzepatide Azelaprag and Tirzepatide: A Look at the Investigational Combination for Obesity and Metabolic Health

Azelapragoral The intersection of pharmaceutical innovation and the pursuit of effective weight management and metabolic health solutions is a dynamic field. Currently, significant interest is focused on azelaprag, an investigational oral apelin receptor agonist, and its potential combination with tirzepatide, a well-established GLP-1/GIP receptor agonist. This combination has been explored in clinical trials, particularly for the treatment of obesity, with efforts to understand its efficacy and safety profile.

Azelaprag, developed by BioAge Labs, is identified by the code BGE-105.2024年8月21日—Azelapragis under investigation in clinical trial NCT06515418(Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared ... It has been under investigation for its potential role in Glycemic Control and its effects on obesity. Early preclinical research, as noted by BioAge, has suggested that azelaprag demonstrates significant glycemic benefits in preclinical models of diabetic obesity, both as a monotherapy and in combination with tirzepatide.2024年12月6日—STRIDES is a randomized, double-blind, placebo-controlled Phase 2 clinical trial ofazelapragas monotherapy and in combination withtirzepatide... Furthermore, azelaprag has shown promise in restoring muscle function. Grid hang assays have indicated that azelaprag can fully restore muscle function to that of lean controls in certain models, a desirable outcome when considering body composition changes associated with weight loss.BioAge Announces Groundbreaking Obesity Treatment Trial

Tirzepatide, marketed under various brand names, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It has demonstrated substantial efficacy in promoting weight loss and improving glycemic control in individuals with type 2 diabetes and obesity.BioAge axes STRIDES trial evaluating azelaprag in ... The Tirzepatide mechanism of action involves mimicking the actions of these incretin hormones, leading to improved insulin sensitivity, reduced appetite, and delayed gastric emptying. Understanding how much weight you can lose on tirzepatide is a common inquiry, with studies showing significant reductions in body weight.

The combination of azelaprag and tirzepatide has been a focal point of BioAge Labs' research, primarily through the STRIDES Phase 2 C clinical trial. This trial was designed to evaluate azelaprag as monotherapy and in conjunction with tirzepatide for the treatment of obesity. Specifically, BioAge has previously linked the combination of azelaprag and tirzepatide to better weight loss outcomes than tirzepatide alone in preclinical mice studies, fueling further investigation to see if this is replicated in human clinical trials. The trial aimed to assess the efficacy of azelaprag when combined with tirzepatide in adults aged 55 and over dealing with obesity. Participants in the STRIDES Phase 2 C trial were required to be willing to take oral medication daily or twice a day, and receive weekly injections of tirzepatide.

Clinical trial NCT06515418, also known as the Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide, has been a key platform for investigating this combination.NCT06515418 | Efficacy and Safety of Oral Azelaprag Plus ... This trial seeks to determine if the addition of oral azelaprag to tirzepatide treatment will amplify overall weight loss in participants. This study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide.

However, the development path for this investigational combination has encountered hurdlesAzelapragis under investigation in clinical trial NCT06515418(Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared With Tirzepatide .... In December 2024, BioAge Labs announced the decision to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss, citing liver safety concerns as the reason for halting the STRIDES Phase II study of azelaprag for obesity.2024年11月4日—In mid-2024, BioAge initiated a Phase 2 trial ofazelaprag in combination with tirzepatidefor the treatment of obesity in older adults. This led to a significant impact on BioAge's stock price. Despite the discontinuation of the STRIDES trial, earlier announcements indicated that azelaprag and tirzepatide are expected to start in mid-2024 for phase II studies, suggesting initial plans for proceeding with clinical evaluation.

The exploration of azelaprag and its drug interactions, alongside its mechanism of action, is crucial for understanding its therapeutic potential225-OR: The Oral Apelin Receptor Agonist Azelaprag .... While the STRIDES trial has been discontinued, the underlying research into azelaprag, an orally available apelin receptor agonist, continues to be of interest2024年12月6日—The trial was designed to study two oral doses ofazelaprag in combination with tirzepatide, which is the active ingredient in Lilly's diabetes .... The potential for azelaprag to enhance metabolic profiles, particularly the Glycemic Control aspects, remains a subject of scientific inquiry. The scientific community will await further data and potential alternative development pathways for BGE-105 (azelaprag), especially in light of its proposed role in combination therapies with agents like tirzepatide. The entire landscape of investigational obesity and metabolic treatments, including emerging azelapragpeptide candidates and the availability of azelapragoral formulations, highlights the ongoing pursuit of novel therapeutic strategies to address these widespread health challenges.